Odiparcil QT Definitive Study

Stopped early · Phase 1

Conditions studied: Fibrillation, Atrial, Atrial Fibrillation

In brief

This study is being completed to demonstrate the lack of effect of repeat dosing with Odiparcil on the QTc interval.

Key facts

Study ID

NCT00437242

Run by

GlaxoSmithKline

People needed

54

Starts

2006-10-01

Last updated by the study team

2012-06-04

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

Where it is running

• GSK Investigational Site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.